{
    "2021-09-29": [
        [
            {
                "time": "2023-10-15",
                "original_text": "AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Qulipta",
                        "FDA",
                        "Migraine",
                        "Drug Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Here's How a New Investor Started Her Portfolio With Just 10 Top Stocks",
                "features": {
                    "keywords": [
                        "Investor",
                        "Portfolio",
                        "Top Stocks"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie",
                "features": {
                    "keywords": [
                        "FDA",
                        "CGRP",
                        "Receptor",
                        "Migraine",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug",
                "features": {
                    "keywords": [
                        "Biotech",
                        "AbbVie",
                        "Migraine",
                        "FDA",
                        "Amicus",
                        "Gene Therapy",
                        "Geovax",
                        "Cancer Drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Healthcare",
                        "Long-Term",
                        "Investors"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}